163 related articles for article (PubMed ID: 23088873)
1. HDAC inhibitors and chaperone function.
Rao R; Fiskus W; Ganguly S; Kambhampati S; Bhalla KN
Adv Cancer Res; 2012; 116():239-62. PubMed ID: 23088873
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors in cancer therapy.
Lane AA; Chabner BA
J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
[TBL] [Abstract][Full Text] [Related]
3. Induction of GRP78 by valproic acid is dependent upon histone deacetylase inhibition.
Shi Y; Gerritsma D; Bowes AJ; Capretta A; Werstuck GH
Bioorg Med Chem Lett; 2007 Aug; 17(16):4491-4. PubMed ID: 17566732
[TBL] [Abstract][Full Text] [Related]
4. Development and therapeutic impact of HDAC6-selective inhibitors.
Dallavalle S; Pisano C; Zunino F
Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
[TBL] [Abstract][Full Text] [Related]
5. The chaperone proteins HSP70, HSP40/DnaJ and GRP78/BiP suppress misfolding and formation of β-sheet-containing aggregates by human amylin: a potential role for defective chaperone biology in Type 2 diabetes.
Chien V; Aitken JF; Zhang S; Buchanan CM; Hickey A; Brittain T; Cooper GJ; Loomes KM
Biochem J; 2010 Nov; 432(1):113-21. PubMed ID: 20735358
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of resistance to histone deacetylase inhibitors.
Lee JH; Choy ML; Marks PA
Adv Cancer Res; 2012; 116():39-86. PubMed ID: 23088868
[TBL] [Abstract][Full Text] [Related]
7. Development of histone deacetylase inhibitors for cancer treatment.
Marchion D; Münster P
Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
[TBL] [Abstract][Full Text] [Related]
8. FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70.
Wang Y; Wang SY; Zhang XH; Zhao M; Hou CM; Xu YJ; Du ZY; Yu XD
Biochem Biophys Res Commun; 2007 May; 356(4):998-1003. PubMed ID: 17397803
[TBL] [Abstract][Full Text] [Related]
9. Targeting histone deacetylase in cancer therapy.
Lin HY; Chen CS; Lin SP; Weng JR; Chen CS
Med Res Rev; 2006 Jul; 26(4):397-413. PubMed ID: 16450343
[TBL] [Abstract][Full Text] [Related]
10. Cardiac histones are substrates of histone deacetylase activity in hemorrhagic shock and resuscitation.
Lin T; Alam HB; Chen H; Britten-Webb J; Rhee P; Kirkpatrick J; Koustova E
Surgery; 2006 Mar; 139(3):365-76. PubMed ID: 16546502
[TBL] [Abstract][Full Text] [Related]
11. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
Richon VM
Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathways: old drugs define new pathways: non-histone acetylation at the crossroads of the DNA damage response and autophagy.
Botrugno OA; Robert T; Vanoli F; Foiani M; Minucci S
Clin Cancer Res; 2012 May; 18(9):2436-42. PubMed ID: 22512979
[TBL] [Abstract][Full Text] [Related]
13. Signaling alterations caused by drugs and autophagy.
Dent P; Booth L; Poklepovic A; Hancock JF
Cell Signal; 2019 Dec; 64():109416. PubMed ID: 31520735
[TBL] [Abstract][Full Text] [Related]
14. HDAC inhibitors for the treatment of cancer.
Secrist JP; Zhou X; Richon VM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylation as a target for radiosensitization.
Cerna D; Camphausen K; Tofilon PJ
Curr Top Dev Biol; 2006; 73():173-204. PubMed ID: 16782459
[TBL] [Abstract][Full Text] [Related]
16. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
Yoshida M; Shimazu T; Matsuyama A
Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
[TBL] [Abstract][Full Text] [Related]
17. Role of histone deacetylase inhibitors in the treatment of cancer (Review).
Mei S; Ho AD; Mahlknecht U
Int J Oncol; 2004 Dec; 25(6):1509-19. PubMed ID: 15547685
[TBL] [Abstract][Full Text] [Related]
18. Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.
Kelly WK; Marks PA
Nat Clin Pract Oncol; 2005 Mar; 2(3):150-7. PubMed ID: 16264908
[TBL] [Abstract][Full Text] [Related]
19. A DNAJB chaperone subfamily with HDAC-dependent activities suppresses toxic protein aggregation.
Hageman J; Rujano MA; van Waarde MA; Kakkar V; Dirks RP; Govorukhina N; Oosterveld-Hut HM; Lubsen NH; Kampinga HH
Mol Cell; 2010 Feb; 37(3):355-69. PubMed ID: 20159555
[TBL] [Abstract][Full Text] [Related]
20. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
Lai JP; Yu C; Moser CD; Aderca I; Han T; Garvey TD; Murphy LM; Garrity-Park MM; Shridhar V; Adjei AA; Roberts LR
Gastroenterology; 2006 Jun; 130(7):2130-44. PubMed ID: 16762634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
